New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:32 EDTXOMAXOMA downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded XOMA following the Phase II trial failure of gevokizumab in Erosive Osteoarthritis of the Hand.
News For XOMA From The Last 14 Days
Check below for free stories on XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XOMA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use